Lung Cancer Dispatch
4.7K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Roche Lung Cancer Pill Gets Reprieve in UK Reversal

"Britain's health cost watchdog NICE on Friday reversed an earlier decision to limit the use of Roche's Tarceva cancer pill on the state health service in a move the drugmaker said would help around 2,000 patients a year.


"New draft guidance from the National Institute for Health and Clinical Excellence (NICE) now backs use of Tarceva for people with non-small-cell lung cancer that has progressed after chemotherapy in wider circumstances than originally suggested."

Cancer Commons's insight:

Reuters  |  Apr 3, 2014

more...
No comment yet.
Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

‘Early Access’ Scheme Unveiled for Innovative Medicines

‘Early Access’ Scheme Unveiled for Innovative Medicines | Lung Cancer Dispatch | Scoop.it

"People with advanced cancer and other serious illnesses like dementia could soon benefit from early access to innovative and promising treatments.

"The Early Access to Medicines scheme would enable safe and promising drugs to be 'fast tracked' into the NHS before they have even been granted a licence for use.

"The new scheme will allow patients without other treatment options to be given experimental drugs that have not yet been licensed but that have been deemed safe and effective through clinical trials.

"Experts will carry out a rapid analysis of the treatment before labelling it a 'promising innovative medicine'.

"The Medicines and Healthcare products Regulatory Agency (MHRA) will then offer a scientific opinion based on a medicine’s risks and benefits. If the benefits are found to outweigh the risks, doctors will be given the green light to offer the drug to patients."


Editor's Note: This UK program is similar to a program already in place in the US that allows patients to request access to drugs still being tested in clinical trials. Even though so-called "compassionate access" is possible, the process can be quite difficult for patients. Learn more about it  from our blog feature on the topic.

Cancer Commons's insight:

Cancer Research UK  |  Mar 14, 2014

more...
Cancer Commons's curator insight, March 14, 2014 5:10 PM

Cancer Research UK  |  Mar 14, 2014

Cancer Commons's curator insight, March 14, 2014 5:14 PM

Cancer Research UK  |  Mar 14, 2014

Scooped by Cancer Commons
Scoop.it!

NICE to Bar Second-Line Use of Tarceva

NICE to Bar Second-Line Use of Tarceva | Lung Cancer Dispatch | Scoop.it

"A proposal by (National Health Service) NHS cost regulators to no longer back the second-line use of Tarceva (erlotinib) to treat relapsed non-small cell lung cancer (NSCLC) has angered the drug's manufacturer Roche and will no doubt come as a shock to patients.


"Following a review of existing guidance, the National Institute for Health and Care Excellence (NICE) has decided that treatment with Tarceva after first-line therapy has failed is no longer a cost-effective option for the NHS.

 

"According to Roche, the move means that more than 1,000 patients in England and Wales every year will be at risk from being left without an active second-line treatment option."

Cancer Commons's insight:

PharmaTimes  |  Feb 4, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

NICE Draft Guidance Recommends Boehringer Ingelheim’s Giotrif

NICE Draft Guidance Recommends Boehringer Ingelheim’s Giotrif | Lung Cancer Dispatch | Scoop.it

"UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new draft guidance recommending German family-owned drug major Boehringer Ingelheim’s Giotrif (afatinib) as an option for treating locally-advanced or metastatic non-small-cell lung cancer (NSCLC) in people whose tumors test positive for the EGFR-TK mutation and have not received a EGFR-TK inhibitor."


Editor's Note: In the US, this drug is called Gilotrif. It is meant for patients whose tumors have a mutation in the EGFR gene, as detected by molecular testing. Learn more about molecular testing to guide treatment decisions.

Cancer Commons's insight:

The Pharma Letter  |  Mar 17, 2014

more...
No comment yet.
Rescooped by Cancer Commons from Melanoma Dispatch
Scoop.it!

Cancer Patients Diagnosed More Quickly

Cancer Patients Diagnosed More Quickly | Lung Cancer Dispatch | Scoop.it

"The time taken to diagnose some of the more common cancers—from the point when a patient first reports a possible symptom to their general practitioner (GP)– fell in adults by an average of five days in just under a decade, according to research published in the British Journal of Cancer."


Editor's Note: In the study, time from first symptoms to cancer diagnosis fell from an average of 125 to 120 days in 7 years, for adults in the UK.

Cancer Commons's insight:

Cancer Research UK  |  Feb 5, 2014

more...
Cancer Commons's curator insight, February 7, 2014 1:56 PM

Cancer Research UK  |  Feb 5, 2014

Cancer Commons's curator insight, February 7, 2014 1:57 PM

Cancer Research UK  |  Feb 5, 2014